Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

37 results

Page 1 of 2

  • Cetuximab in the management of nasopharyngeal carcinoma – a narrative review
  • M S Iqbal, D Wilkinson, A Tin, P Bossi, L Gradwell-Nelson, J Kovarik, J O'Hara, C Kelly
  • Journal: The Journal of Laryngology & Otology / Volume 133 / Issue 10 / October 2019
  • Published online by Cambridge University Press: 11 September 2019, pp. 843-855
  • Print publication: October 2019
  • View abstract
    Background

    Concurrent chemotherapy with radiotherapy is the standard treatment for locoregionally advanced nasopharyngeal cancer. Cetuximab can be used in the treatment of head and neck squamous cell carcinoma. However, the randomised studies that led to approval for its use in this setting excluded nasopharyngeal cancer. In the context of limited data for the use of cetuximab in nasopharyngeal cancer in the medical literature, this review aimed to summarise the current evidence for its use in both primary and recurrent or metastatic disease.

    Method

    A literature search was performed using the keywords ‘nasopharyngeal neoplasm’, ‘cetuximab’ and ‘Erbitux’.

    Results

    Twenty studies were included. There were no randomised phase III trials, but there were nine phase II trials. The use of cetuximab in the treatment of nasopharyngeal carcinoma has been tested in various settings, including in combination with induction chemotherapy and concurrent chemoradiotherapy, and in the palliative setting.

    Conclusion

    There is no evidence of benefit from the addition of cetuximab to standard management protocols, and there is some evidence of increased toxicity. There is more promise for its use in metastatic or locally recurrent settings. This review draws together the existing evidence and could provide a focus for future studies.

  • Environmental TEM Study of Oxidation Processes of Catalytic Nanoparticles
  • L. Kovarik, Z. Wei, C.H.F. Peden, J. Szanyi
  • Journal: Microscopy and Microanalysis / Volume 25 / Issue S2 / August 2019
  • Published online by Cambridge University Press: 05 August 2019, pp. 1446-1447
  • Print publication: August 2019
    • Article
      • You have access
    • PDF
    • Export citation
  • Reducing the Missing Wedge in TEM Tomography
  • A. Genc, L. Kovarik, L. Pullan, J. Ringnalda
  • Journal: Microscopy and Microanalysis / Volume 22 / Issue S3 / July 2016
  • Published online by Cambridge University Press: 25 July 2016, pp. 26-27
  • Print publication: July 2016
    • Article
      • You have access
    • PDF
    • Export citation
  • The Effect of Probe Correctors on the Analytical Results of Non-ideal Samples
  • J. Ringnalda, A. Genc, L. Kovarik
  • Journal: Microscopy and Microanalysis / Volume 20 / Issue S3 / August 2014
  • Published online by Cambridge University Press: 27 August 2014, pp. 566-567
  • Print publication: August 2014
    • Article
      • You have access
    • PDF
    • Export citation

Page 1 of 2